Showing results (401-410 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinomaAnne-Sophie Boudy, Noémie Grausz, Lise Selleret, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinomaChristi M J Steendam, Robert Peric, Nico C van Walree, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2020
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)Véronique Hofman, Jonathan Benzaquen, Simon Heeke, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2020
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitorsYing Cheng, Lixia Ma, Ying Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapyKazuki Takada, Shinkichi Takamori, Yasuto Yoneshima, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Image-based ex vivo drug screen to assess targeted therapies in recurrent thymomaAntti Arjonen, Rami Mäkelä, Ville Härmä, et al.
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factorsDonella Puliti, Mario Mascalchi, Francesca Maria Carozzi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2020
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft modelsSebastiao N Martins-Filho, Jessica Weiss, Nhu-An Pham, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?Sanjay Popat, Christian Grohé, Jesus Corral, et al.
Pageof 701